英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Beihilfe查看　Beihilfe　在百度字典中的解释百度英翻中〔查看〕
Beihilfe查看　Beihilfe　在Google字典中的解释Google英翻中〔查看〕
Beihilfe查看　Beihilfe　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Canadas Drug Agency | CDA-AMC
    Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and
  • MED-LIFE DISCOVERIES
    Med-life discoveries is a clinical-stage biopharma company developing novel plasmalogen-based therapeutics for the treatment of Rhizomelic Chondrodysplasia Punctata(RCDP) and other neurological conditions* Learn more about plasmalogens
  • Canada reviews newborn screening for MLD - LinkedIn
    Canada's Drug Agency is welcoming patient and clinician input for their review of newborn screening for early-onset Metachromatic leukodystrophy (MLD)
  • Drugs for Rare Diseases - Newborn Screening Activities | CDA-AMC
    Metachromatic leukodystrophy (MLD) is a rare inherited condition that causes nerve damage and is estimated to affect less than 1 of 100,000 live births In its early-onset form, MLD causes substantial disability, high caregiver burden, and results in premature mortality
  • SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE . . . - MED-LIFE DISCOVERIES
    MLD is a biopharma company located in Saskatoon, Saskatchewan, Canada which is developing a pipeline of plasmalogen-based drugs, including PPI-1011, for RCDP and other neurological indications
  • Newborn Screening for Metachromatic Leukodystrophy | CDA-AMC
    As a part of the Government of Canada’s National Strategy for Drugs for Rare Diseases, Canada’s Drug Agency supported the development of pan-Canadian guidance for newborn screening
  • Open Call for Patient and Clinician Input - NBS for MLD | CDA-AMC
    Canada’s Drug Agency welcomes patient and clinician input for the review of newborn screening for early-onset metachromatic leukodystrophy (MLD) The input we receive will be published in full on our website and used to inform the evidence review
  • CDA landing page | CDA-AMC
    Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and
  • Drug Product Database: Access the database - Canada. ca
    Search the Drug Product Database (DPD) to find drugs authorized for sale by Health Canada The DPD is updated nightly and includes: Generic drug manufacturers must update their PM to ensure it aligns with the Canadian Reference Product
  • CDA-AMC - CANADA’S DRUG AGENCY – L’AGENCE DES . . . - INAHTA
    Canada’s health administrators and policy experts rely on CDA-AMC to help inform their decisions about the life cycle management of drugs, devices, and services used to prevent, diagnose, and treat medical conditions





中文字典-英文字典  2005-2009